SCHEMBL25889282

SCHEMBL25889282

C[C@H](Oc1cc(Br)ccc1[N+](=O)[O-])c1ccc(Cl)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 3/20 0.40
TSHR P16473 1/20 0.40
SLC6A4 P31645 3/20 0.39
HTR2C P28335 1/20 0.39
HTR2B P41595 1/20 0.39
HTR6 P50406 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.36
ALDH1A1 P00352 2/20 0.36
LMNA P02545 2/20 0.36
MAPT P10636 2/20 0.36
TP53 P04637 1/20 0.36
HPGD P15428 1/20 0.36
PDE7A Q13946 2/20 0.36
PDE7B Q9NP56 1/20 0.36
VCAM1 P19320 1/20 0.35
PDK1 Q15118 1/20 0.34
ABCB1 P08183 1/20 0.34
ABCC1 P33527 1/20 0.34
S1PR4 O95977 3/20 0.34
JAK2 O60674 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31402301 1.00 MAPK1 (0.40) MAPK1TSHRSLC6A4HTR2CHTR2B
SCHEMBL29024322 1.00 MAPK1 (0.40) MAPK1TSHRSLC6A4HTR2CHTR2B
SCHEMBL25298519 0.87 TDP1 (0.40) SLC6A4SMN1; SMN2ALDH1A1LMNAMAPT
SCHEMBL25256796 0.87 TDP1 (0.40) SLC6A4SMN1; SMN2ALDH1A1LMNAMAPT
SCHEMBL18582829 0.86 LRRK2 (0.42) MAPK1SLC6A4HTR2CHTR2BHTR6
SCHEMBL18582827 0.86 LRRK2 (0.42) MAPK1SLC6A4HTR2CHTR2BHTR6
SCHEMBL29509060 0.80 PDK1 (0.47) MAPK1TSHRSMN1; SMN2ALDH1A1LMNA
SCHEMBL7481571 0.80 PDK1 (0.47) MAPK1TSHRSMN1; SMN2ALDH1A1LMNA
SCHEMBL24133484 0.76 SLC6A4 (0.43) SLC6A4HTR2CHTR2BHTR6SMN1; SMN2
SCHEMBL31402228 0.76 SLC6A4 (0.43) SLC6A4HTR2CHTR2BHTR6SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4741018-A2 SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2026-05-13 EP disclosed
US-12583836-B2 Sulphonamide compounds Anaxis Pharma Pty Ltd (AU) 2026-03-24 US disclosed
EP-4168401-B1 SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2026-01-07 EP disclosed
US-20250074891-A1 BIFUNCTIONAL SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2025-03-06 US disclosed
EP-4452966-A1 BIFUNCTIONAL SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2024-10-30 EP disclosed
US-20230227429-A1 SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2023-07-20 US disclosed
US-20230227429-A1 SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2023-07-20 US disclosed
WO-2023115149-A1 BIFUNCTIONAL SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2023-06-29 WO disclosed
EP-4168401-A1 SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2023-04-26 EP disclosed
CN-115956070-A Sulfonamide compounds 阿纳克西斯制药股份有限公司 2023-04-11 CN disclosed
WO-2021253095-A1 SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2021-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250074891-A1 BIFUNCTIONAL SULPHONAMIDE COMPOUNDS MLKL, RIPK3, CASP9 MAPK1 671/4885TSHR 4279/4885SLC6A4 2435/4885
US-12583836-B2 Sulphonamide compounds MLKL, RIPK3, CASP1 MAPK1 176/4885TSHR 1614/4885SLC6A4 1358/4885
US-20230227429-A1 SULPHONAMIDE COMPOUNDS MLKL, RIPK3, CASP1 MAPK1 174/4885TSHR 4177/4885SLC6A4 2236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.